Advanced search
Publication Cover
Journal of Inflammation Research Volume 17, 2024 - Issue
Submit an article Journal homepage
173
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Association of Antidiabetic Drug Target Genes with Inflammatory Bowel Disease: A Mendelian Randomization Study

Xiangli Qing1 Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China;2 School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of ChinaView further author information
,
Lin Wang1 Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of ChinaView further author information
,
Shuangshuang Fang1 Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of ChinaView further author information
,
Yanran Ban1 Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China;3 Graduate School of Beijing University of Chinese Medicine, Beijing, People’s Republic of ChinaView further author information
,
Zhuotai Zhong1 Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of ChinaView further author information
,
Weiqi Sun1 Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of ChinaView further author information
,
Chenhui Zhang4 Department of General Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of ChinaView further author information
,
Tao Zhang1 Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of ChinaView further author information
,
Yang Yang1 Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of ChinaView further author information
&
Wei Wei1 Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1389-1396 | Received 18 Oct 2023, Accepted 03 Feb 2024, Published online: 29 Feb 2024

References

  • Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. doi:10.1038/s41572-020-0205-x
  • Roda G, Chien Ng S, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers. 2020;6(1):22. doi:10.1038/s41572-020-0156-2
  • Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0
  • Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402(10401):571–584. doi:10.1016/S0140-6736(23)00966-2
  • Magliano DJ, Sacre JW, Harding JL, et al. Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. Nat Rev Endocrinol. 2020;16(6):321–331. doi:10.1038/s41574-020-0334-z
  • Rohm TV, Meier DT, Olefsky JM, et al. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31–55. doi:10.1016/j.immuni.2021.12.013
  • Kang EA, Han K, Chun J, et al. Increased risk of diabetes in inflammatory bowel disease patients: a nationwide population-based study in Korea. J Clin Med. 2019;8(3):343. doi:10.3390/jcm8030343
  • Jess T, Jensen BW, Andersson M, et al. Inflammatory bowel diseases increase risk of type 2 diabetes in a nationwide cohort study. Clin Gastroenterol Hepatol. 2020;18(4):881–8.e1. doi:10.1016/j.cgh.2019.07.052
  • Demarsilis A, Reddy N, Boutari C, et al. Pharmacotherapy of type 2 diabetes: an update and future directions.. Metabolism. 2022;137:155332. doi:10.1016/j.metabol.2022.155332
  • Chauquet S, Zhu Z, O’donovan MC, et al. Association of antihypertensive drug target genes with psychiatric disorders: a Mendelian randomization study. JAMA Psychiatry. 2021;78(6):623–631. doi:10.1001/jamapsychiatry.2021.0005
  • Huang W, Xiao J, Ji J, et al. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. Elife. 2021;2021:10.
  • Chen J, Spracklen CN, Marenne G, et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet. 2021;53(6):840–860. doi:10.1038/s41588-021-00852-9
  • Mahajan A, Spracklen CN, Zhang W, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54(5):560–572. doi:10.1038/s41588-022-01058-3
  • De Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49(2):256–261. doi:10.1038/ng.3760
  • Fang S, Yarmolinsky J, Gill D, et al. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: a Mendelian randomisation study. PLoS Med. 2023;20(1):e1003988. doi:10.1371/journal.pmed.1003988
  • Chen X, Kong J, Pan J, et al. Kidney damage causally affects the brain cortical structure: a Mendelian randomization study. EBioMedicine. 2021;72:103592. doi:10.1016/j.ebiom.2021.103592
  • Wang T, Yang JY, Buse JB, et al. Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease: real-world evidence in U.S. Adults Diabetes Care. 2019;42(11):2065–2074. doi:10.2337/dc19-0162
  • Radel JA, Pender DN, Shah SA. Dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease risk: a meta-analysis. Ann Pharmacother. 2019;53(7):697–704. doi:10.1177/1060028019827852
  • Abrahami D, Douros A, Yin H, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ. 2018;360:k872. doi:10.1136/bmj.k872
  • Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55(9):1341–1349. doi:10.1136/gut.2006.093484
  • Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134(3):688–695. doi:10.1053/j.gastro.2007.12.012
  • Liang HL, Ouyang Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol. 2008;14(1):114–119. doi:10.3748/wjg.14.114
  • Pedersen G, Brynskov J. Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. Am J Gastroenterol. 2010;105(7):1595–1603. doi:10.1038/ajg.2009.749
  • Zuber V, Grinberg NF, Gill D, et al. Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches. Am J Hum Genet. 2022;109(5):767–782. doi:10.1016/j.ajhg.2022.04.001

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.